Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$46.55 USD
-0.83 (-1.75%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $46.57 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Agios Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 777 | 783 | 1,020 | 573 | 565 |
Receivables | 3 | 2 | 4 | 25 | 15 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 19 | 8 | 0 | 15 | 7 |
Other Current Assets | 35 | 39 | 40 | 24 | 24 |
Total Current Assets | 834 | 833 | 1,064 | 637 | 612 |
Net Property & Equipment | 15 | 23 | 29 | 32 | 31 |
Investments & Advances | 29 | 314 | 266 | 98 | 153 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 4 | 4 | 3 | 1 | 0 |
Total Assets | 937 | 1,239 | 1,438 | 853 | 891 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 10 | 19 | 17 | 27 | 22 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 43 | 30 | 32 | 60 | 53 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 11 |
Total Current Liabilities | 68 | 63 | 60 | 94 | 93 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 51 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 1 |
Other Non-Current Liabilities | 1 | 3 | 0 | 261 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 126 | 138 | 146 | 453 | 250 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,437 | 2,386 | 2,334 | 2,243 | 2,156 |
Retained Earnings | -823 | -471 | -239 | -1,843 | -1,516 |
Other Equity | 0 | -13 | -1 | 0 | 0 |
Treasury Stock | 802 | 802 | 802 | 0 | 0 |
Total Shareholder's Equity | 811 | 1,101 | 1,292 | 400 | 641 |
Total Liabilities & Shareholder's Equity | 937 | 1,239 | 1,438 | 853 | 891 |
Total Common Equity | 811 | 1,101 | 1,292 | 400 | 641 |
Shares Outstanding | 55.80 | 54.90 | 54.30 | 69.30 | 58.80 |
Book Value Per Share | 14.53 | 20.05 | 23.79 | 5.76 | 10.89 |
Fiscal Year End for Agios Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 570 | 598 | 777 | 647 | 703 |
Receivables | 4 | 3 | 3 | 1 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 24 | 23 | 19 | 17 | 16 |
Other Current Assets | 35 | 39 | 35 | 38 | 37 |
Total Current Assets | 632 | 664 | 834 | 704 | 757 |
Net Property & Equipment | 13 | 14 | 15 | 17 | 20 |
Investments & Advances | 75 | 116 | 29 | 225 | 244 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 4 | 4 | 4 | 4 | 4 |
Total Assets | 773 | 850 | 937 | 1,007 | 1,085 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 10 | 11 | 10 | 13 | 12 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 37 | 25 | 43 | 30 | 29 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 63 | 52 | 68 | 58 | 55 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 1 | 1 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 113 | 106 | 126 | 120 | 121 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,464 | 2,452 | 2,437 | 2,422 | 2,411 |
Retained Earnings | -1,000 | -904 | -823 | -727 | -635 |
Other Equity | -1 | -1 | 0 | -6 | -9 |
Treasury Stock | 802 | 802 | 802 | 802 | 802 |
Total Shareholder's Equity | 661 | 744 | 811 | 887 | 964 |
Total Liabilities & Shareholder's Equity | 773 | 850 | 937 | 1,007 | 1,085 |
Total Common Equity | 661 | 744 | 811 | 887 | 964 |
Shares Outstanding | 56.80 | 56.70 | 55.80 | 55.80 | 55.70 |
Book Value Per Share | 11.63 | 13.12 | 14.53 | 15.89 | 17.31 |